Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [911]
News [3678]
Articles [22]
Editorials [1]
Conferences [135]
elearning [0]
Editor’s Choice for May 2018
Prof Gordon McVie - Founding Editor, ecancer
Editor’s Choice for May 2018 ( Prof Gordon McVie - Founding Editor, ecancer )
21 May 2018
Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer
Dr Arjun Balar - NYU Langone Medical Center, New York, USA
Dose escalation of durvalumab with tremelimumab for metastatic urothelial cancer ( Dr Arjun Balar - NYU Langone Medical Center, New York, USA )
25 Apr 2018
Phase I taselisib results and a cell-free DNA assay
Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA
Phase I taselisib results and a cell-free DNA assay ( Dr José Baselga - Memorial Sloan Kettering Cancer Center, New York, USA )
25 Apr 2018
Safety indications in mouse models treated with full doses of MEK inhibitors...
Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York...
Safety indications in mouse models treated with full doses of MEK inhibitors and SHP099 ( Dr Carmine Fedele - Laura and Isaac Perlmutter Cancer Center at New York University Langone Medical, New York, USA )
25 Apr 2018
A variety of approaches to measure the efficacy of PARP inhibitors
Dr Elisabetta Leo - AstraZeneca, Cambridge, UK
A variety of approaches to measure the efficacy of PARP inhibitors ( Dr Elisabetta Leo - AstraZeneca, Cambridge, UK )
25 Apr 2018
Development and clinical indications of PARP inhibitors
Dr Mark O'Connor - AstraZeneca, Cambridge, UK
Development and clinical indications of PARP inhibitors ( Dr Mark O'Connor - AstraZeneca, Cambridge, UK )
25 Apr 2018
Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL
Dr Susan Galbraith - AstraZeneca, Cambridge, UK
Mechanisms and prospects of a novel CDK9 inhibitor for DLBCL ( Dr Susan Galbraith - AstraZeneca, Cambridge, UK )
25 Apr 2018
Clinical development and economic prospects of CAR T cell immunotherapies
Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA
Clinical development and economic prospects of CAR T cell immunotherapies ( Dr Bob Velamehr - Fate Therapeutics, La Jolla, USA )
25 Apr 2018
The best sequence of anti-HER2 therapy in metastatic breast cancer
Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain
The best sequence of anti-HER2 therapy in metastatic breast cancer ( Dr Javier Cortes - Vall d’Hebron University Hospital, Barcelona, Spain )
29 Jan 2018
ESO-ESMO-ABC guidelines in metastatic breast cancer
Dr Nagi El Saghir - American University of Beirut, Beirut, Lebanon
ESO-ESMO-ABC guidelines in metastatic breast cancer ( Dr Nagi El Saghir - American University of Beirut, Beirut, Lebanon )
26 Jan 2018
ESMO 2017 roundup with Dr Bishal Gyawali (2/2)
Dr Bishal Gyawali - Nagoya University, Nagoya, Japan
ESMO 2017 roundup with Dr Bishal Gyawali (2/2) ( Dr Bishal Gyawali - Nagoya University, Nagoya, Japan )
11 Sep 2017
Editor's Choice for July 17
Prof Gordon McVie - Founding Editor, ecancer
Editor's Choice for July 17 ( Prof Gordon McVie - Founding Editor, ecancer )
28 Jul 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation